Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
OrthoSpineNews
JULY 29, 2025
Data readout expected in Q1 2026 MIAMI, July 29, 2025 (GLOBE NEWSWIRE) — Vivex Biologics, Inc., Data from the trial are expected in the first quarter of 2026. “We We look forward to sharing data from ASCEND in early 2026 and continuing to build on the real-world momentum behind VIA Disc NP.”
Let's personalize your content